Overview

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

Status:
Completed

Trial end date:
2009-11-01

Target enrollment:

Participant gender:

Summary

To investigate the influence of different dosage regimen (5 mg twice daily versus 10 mg once daily) on the steady state pharmacokinetics and pharmacodynamics of BI 10773 administered orally

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Empagliflozin